Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Poirier

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|May 20, 2011
Indole 5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase with nanomolar potency in cell-based subgenomic replicons (part 2): central amino acid linker and right-hand-side SAR studiesPierre L Beaulieu, Catherine Chabot, Jianmin Duan, et al.
Angewandte Chemie (International Ed. in English)|September 16, 2004
Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategySteven R LaPlante, Araz Jakalian, Norman Aubry, et al.
Journal of Medicinal Chemistry|October 29, 2013
Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127)Steven R LaPlante, Michael Bös, Christian Brochu, et al.
Journal of Medicinal Chemistry|August 2, 2012
Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV)Pierre L Beaulieu, Michael Bös, Michael G Cordingley, et al.
Bioorganic & Medicinal Chemistry Letters|June 18, 2013
Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotypePierre L Beaulieu, René Coulombe, Jianmin Duan, et al.
Organic Letters|August 28, 2004
Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humansAnne-Marie Faucher, Murray D Bailey, Pierre L Beaulieu, et al.
Plos One|April 8, 2022
Development of mAb-based polyglutamine-dependent and polyglutamine length-independent huntingtin quantification assays with cross-site validationDavid F Fischer, Sipke Dijkstra, Kimberly Lo, et al.
Journal of Medicinal Chemistry|March 19, 2004
Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061Montse Llinàs-Brunet, Murray D Bailey, Gordon Bolger, et al.
Journal of Medicinal Chemistry|June 19, 2013
Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potencyOliver Hucke, René Coulombe, Pierre Bonneau, et al.
Bioorganic & Medicinal Chemistry Letters|January 16, 2010
N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studiesPierre L Beaulieu, Eric Jolicoeur, James Gillard, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|May 20, 2011
Indole 5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase with nanomolar potency in cell-based subgenomic replicons (part 2): central amino acid linker and right-hand-side SAR studiesPierre L Beaulieu, Catherine Chabot, Jianmin Duan, et al.
Angewandte Chemie (International Ed. in English)|September 16, 2004
Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategySteven R LaPlante, Araz Jakalian, Norman Aubry, et al.
Journal of Medicinal Chemistry|October 29, 2013
Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127)Steven R LaPlante, Michael Bös, Christian Brochu, et al.
Journal of Medicinal Chemistry|August 2, 2012
Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV)Pierre L Beaulieu, Michael Bös, Michael G Cordingley, et al.
Bioorganic & Medicinal Chemistry Letters|June 18, 2013
Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotypePierre L Beaulieu, René Coulombe, Jianmin Duan, et al.
Organic Letters|August 28, 2004
Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humansAnne-Marie Faucher, Murray D Bailey, Pierre L Beaulieu, et al.
Plos One|April 8, 2022
Development of mAb-based polyglutamine-dependent and polyglutamine length-independent huntingtin quantification assays with cross-site validationDavid F Fischer, Sipke Dijkstra, Kimberly Lo, et al.
Journal of Medicinal Chemistry|March 19, 2004
Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061Montse Llinàs-Brunet, Murray D Bailey, Gordon Bolger, et al.
Journal of Medicinal Chemistry|June 19, 2013
Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potencyOliver Hucke, René Coulombe, Pierre Bonneau, et al.
Bioorganic & Medicinal Chemistry Letters|January 16, 2010
N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studiesPierre L Beaulieu, Eric Jolicoeur, James Gillard, et al.
Pageof 3